[8-K] Adaptimmune Therapeutics plc American Reports Material Event
Adaptimmune Therapeutics plc announced second-quarter financial results for the period ended June 30, 2025 and provided a corporate update. The Form 8-K furnishes the companys press release as Exhibit 99.1 and states that the furnished information is not deemed "filed" for purposes of Section 18 and is not incorporated by reference except by specific reference.
The filing does not include the financial figures or operational details; the full press release attached as Exhibit 99.1 contains the detailed results and corporate update.
Adaptimmune Therapeutics plc ha annunciato i risultati finanziari del secondo trimestre per il periodo chiuso il 30 giugno 2025 e ha fornito un aggiornamento aziendale. Il Modulo 8-K fornisce il comunicato stampa della società come Exhibit 99.1 e precisa che le informazioni fornite non sono considerate 'depositate' ai fini della Sezione 18 e non sono incorporate per riferimento, salvo espressa indicazione.
La presentazione non include i dati finanziari né i dettagli operativi; il comunicato stampa completo allegato come Exhibit 99.1 contiene i risultati dettagliati e l'aggiornamento aziendale.
Adaptimmune Therapeutics plc anunció los resultados financieros del segundo trimestre correspondientes al periodo terminado el 30 de junio de 2025 y ofreció una actualización corporativa. El Formulario 8-K incorpora el comunicado de prensa de la compañía como Exhibit 99.1 y señala que la información facilitada no se considera 'presentada' a los efectos de la Sección 18 y no se incorpora por referencia, salvo que se indique expresamente.
La presentación no incluye las cifras financieras ni los detalles operativos; el comunicado de prensa completo adjunto como Exhibit 99.1 contiene los resultados detallados y la actualización corporativa.
Adaptimmune Therapeutics plc는 2025년 6월 30일 종료된 기간에 대한 2분기 재무 실적을 발표하고 기업 업데이트를 제공했습니다. Form 8-K는 회사의 보도자료를 Exhibit 99.1로 첨부하며, 제공된 정보는 섹션 18의 목적상 '제출된(filed)' 것으로 간주되지 않으며 특정한 참조로 명시적으로 포함되는 경우를 제외하고는 참조로 통합되지 않는다고 명시합니다.
이번 제출에는 재무 수치나 운영 세부사항이 포함되어 있지 않습니다. 전체 보도자료는 Exhibit 99.1로 첨부되어 있으며 상세한 결과와 기업 업데이트를 담고 있습니다.
Adaptimmune Therapeutics plc a annoncé les résultats financiers du deuxième trimestre pour la période close le 30 juin 2025 et a fourni une mise à jour d'entreprise. Le formulaire 8-K fournit le communiqué de presse de la société en tant que Exhibit 99.1 et indique que les informations fournies ne sont pas considérées comme 'déposées' aux fins de la Section 18 et ne sont pas incorporées par renvoi, sauf mention expresse.
Le dépôt n'inclut pas les chiffres financiers ni les détails opérationnels ; le communiqué de presse complet annexé en tant que Exhibit 99.1 contient les résultats détaillés et la mise à jour d'entreprise.
Adaptimmune Therapeutics plc gab die Finanzergebnisse des zweiten Quartals für den Zeitraum zum 30. Juni 2025 bekannt und veröffentlichte ein Unternehmensupdate. Das Formular 8-K stellt die Pressemitteilung des Unternehmens als Exhibit 99.1 zur Verfügung und erklärt, dass die bereitgestellten Informationen für Zwecke von Section 18 nicht als 'eingereicht' ('filed') gelten und nicht durch Verweis eingegliedert werden, es sei denn, dies geschieht durch ausdrückliche Bezugnahme.
Die Einreichung enthält keine Finanzzahlen oder operativen Details; die vollständige Pressemitteilung als Exhibit 99.1 enthält die ausführlichen Ergebnisse und das Unternehmensupdate.
- Company announced Q2 results for the period ended June 30, 2025 and provided a corporate update as stated in the filing.
- Press release furnished as Exhibit 99.1, making the corporate update and results available in a labeled exhibit.
- Filing does not include financial figures or operational detail in the body of the Form 8-K, so metrics are not available here.
- Information is "furnished" not "filed", which limits automatic incorporation by reference into other SEC filings.
Insights
TL;DR: Routine earnings disclosure furnished; no financial data included in the filing itself, limiting immediate assessment of performance.
The Form 8-K notifies investors that Adaptimmune announced second-quarter results for the period ended June 30, 2025 and furnished a press release as Exhibit 99.1. The company explicitly states the material is "furnished" and not "filed," which limits automatic incorporation into other SEC filings. Because this filing does not contain revenue, profit, cash flow, guidance or other quantitative metrics, the filing alone does not allow evaluation of operational or financial trends; the press release (Exhibit 99.1) must be reviewed for substantive metrics.
TL;DR: Procedural 8-K furnishing a press release and clarifying legal status of the disclosure; appears to be standard corporate reporting practice.
The company furnished a press release and included a customary statement that furnished information is not "filed" under Section 18 and is not incorporated by reference except by specific reference. This language and the exhibit listing (including Exhibit 99.1 and the Inline XBRL cover page) are consistent with routine disclosure practices for earnings announcements and corporate updates. No governance issues, leadership changes, or material transactions are disclosed in this filing.
Adaptimmune Therapeutics plc ha annunciato i risultati finanziari del secondo trimestre per il periodo chiuso il 30 giugno 2025 e ha fornito un aggiornamento aziendale. Il Modulo 8-K fornisce il comunicato stampa della società come Exhibit 99.1 e precisa che le informazioni fornite non sono considerate 'depositate' ai fini della Sezione 18 e non sono incorporate per riferimento, salvo espressa indicazione.
La presentazione non include i dati finanziari né i dettagli operativi; il comunicato stampa completo allegato come Exhibit 99.1 contiene i risultati dettagliati e l'aggiornamento aziendale.
Adaptimmune Therapeutics plc anunció los resultados financieros del segundo trimestre correspondientes al periodo terminado el 30 de junio de 2025 y ofreció una actualización corporativa. El Formulario 8-K incorpora el comunicado de prensa de la compañía como Exhibit 99.1 y señala que la información facilitada no se considera 'presentada' a los efectos de la Sección 18 y no se incorpora por referencia, salvo que se indique expresamente.
La presentación no incluye las cifras financieras ni los detalles operativos; el comunicado de prensa completo adjunto como Exhibit 99.1 contiene los resultados detallados y la actualización corporativa.
Adaptimmune Therapeutics plc는 2025년 6월 30일 종료된 기간에 대한 2분기 재무 실적을 발표하고 기업 업데이트를 제공했습니다. Form 8-K는 회사의 보도자료를 Exhibit 99.1로 첨부하며, 제공된 정보는 섹션 18의 목적상 '제출된(filed)' 것으로 간주되지 않으며 특정한 참조로 명시적으로 포함되는 경우를 제외하고는 참조로 통합되지 않는다고 명시합니다.
이번 제출에는 재무 수치나 운영 세부사항이 포함되어 있지 않습니다. 전체 보도자료는 Exhibit 99.1로 첨부되어 있으며 상세한 결과와 기업 업데이트를 담고 있습니다.
Adaptimmune Therapeutics plc a annoncé les résultats financiers du deuxième trimestre pour la période close le 30 juin 2025 et a fourni une mise à jour d'entreprise. Le formulaire 8-K fournit le communiqué de presse de la société en tant que Exhibit 99.1 et indique que les informations fournies ne sont pas considérées comme 'déposées' aux fins de la Section 18 et ne sont pas incorporées par renvoi, sauf mention expresse.
Le dépôt n'inclut pas les chiffres financiers ni les détails opérationnels ; le communiqué de presse complet annexé en tant que Exhibit 99.1 contient les résultats détaillés et la mise à jour d'entreprise.
Adaptimmune Therapeutics plc gab die Finanzergebnisse des zweiten Quartals für den Zeitraum zum 30. Juni 2025 bekannt und veröffentlichte ein Unternehmensupdate. Das Formular 8-K stellt die Pressemitteilung des Unternehmens als Exhibit 99.1 zur Verfügung und erklärt, dass die bereitgestellten Informationen für Zwecke von Section 18 nicht als 'eingereicht' ('filed') gelten und nicht durch Verweis eingegliedert werden, es sei denn, dies geschieht durch ausdrückliche Bezugnahme.
Die Einreichung enthält keine Finanzzahlen oder operativen Details; die vollständige Pressemitteilung als Exhibit 99.1 enthält die ausführlichen Ergebnisse und das Unternehmensupdate.
FAQ
What did Adaptimmune (ADAP) disclose in this Form 8-K?
Does the Form 8-K include Q2 2025 financial figures for ADAP?
Where can I find the full press release referenced in the 8-K?
Is the furnished press release considered "filed" or incorporated by reference?
What is Adaptimmunes ticker symbol and listing?
